PORTLAND, Maine — Putney Inc., a rapidly growing pet pharmaceutical company focused on the development and sale of generic prescription medicines for pets, has hired Richard Davan as director of Regulatory Affairs, as the company continues to expand its pipeline of FDA-approved veterinary generics.
Davan will lead Putney’s regulatory team and report to Dr. Anthony Lucas, BVMS, PhD, Putney’s Vice President of Research and Development.
Davan comes to Putney from the human pharmaceutical industry, where he gained over 18 years of experience in regulatory affairs in the development and approval of both domestic and international filings. With experience in both pharmaceuticals and biologics, Davan expects the transition to animal health to be smooth. “The FDA has rigorous standards for all drug approvals—human and animal—to ensure that they are safe, effective and high quality products. I’m excited to be part of the team that makes sure that Putney’s veterinary generic drug applications meet those tough standards,” says Davan.
Dr. Lucas says Davan’s leadership skills and regulatory expertise will help Putney develop and commercialize even more veterinary generics. “Rick brings the experience and abilities required to coordinate the regulatory efforts for Putney’s entire range of future products,” says Dr. Lucas.
In 2013, Putney’s regulatory team achieved three FDA-approvals in just ten months, including two first-to-market veterinary generics — Putney Cefpodoxime Proxetil Tablets and Putney Enrofloxacin Flavored Tablets. Three team members who contributed to the successful delivery of Putney’s pipeline were recognized with promotions. Melanie Archer was promoted to Senior Manager of Regulatory Affairs, Qamrul Islam was promoted to Senior Manager of Technical Chemistry, Manufacturing and Control and Dr. Frank Femia, PhD was promoted to Senior Manager of Product Development.
Putney is a pharmaceutical company committed to providing high quality, cost-effective generic medicines for pets. Putney’s reliable supply of affordable drug options empowers veterinarians, allowing them to provide the best possible medicine at the best possible price, and supports pet owners, helping them afford to comply with veterinary recommendations. Putney’s ongoing investment in research and development is focused on creating the next generation of generic veterinary products based on inputs from companion animal veterinarians and its industry partners. Learn more atwww.putneyvet.com.
This post was contributed by a community member. Submit your news →